Allogene Therapeutics, Inc. (NasdaqGS: ALLO)
Health Care · Biotechnology · US
$1.25
-6.02% today · +3.3% 1Y
Allogene Therapeutics, Inc. (NasdaqGS: ALLO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $431.86M and employs 151 people.
Over the last twelve months the share price has gained 3.3%, trading between 1.04 and 4.46.
Tweenvest scores Allogene Therapeutics, Inc. across four factors: quality 36/100, value 45/100. Its strongest factor is value.
ALLO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $431.86M
- Revenue (TTM)
- $4.64M
- P/E
- —
- EPS
- -0.65
- Dividend yield
- —
- Beta (5Y)
- 0.56
- 52-week high
- $4.46
- 52-week low
- $1.04
- Avg volume (3M)
- —
- Shares outstanding
- 345.49M
- Employees
- 151
- Next earnings
- —
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
- ISIN
- US0197701065
- Founded
- 2017
- Listed since
- Oct 11, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eupraxia Pharmaceuticals Inc.TSX: EPRX | $435.64M | CA$9.35 | -12.04% |
| Avacta Group PlcAIM: AVCT | $435.09M | £0.67 | +2.29% |
| Egetis Therapeutics AB (publ)OM: EGTX | $433.80M | Skr9.24 | -6.95% |
| Eikon Therapeutics, Inc.NasdaqGS: EIKN | $433.32M | $8.00 | -2.20% |
| Assembly Biosciences, Inc.NasdaqGS: ASMB | $431.44M | $21.19 | +5.11% |
| ACRO Biomedical Co., Ltd.TPEX: 6748 | $429.72M | NT$194.50 | -8.69% |
| Prothena Corporation plcNasdaqGS: PRTA | $428.66M | $8.35 | -5.54% |
| MapLight Therapeutics, Inc.NasdaqGS: MPLT | $427.93M | $7.70 | -12.80% |
Figures last refreshed Oct 18, 2026.